A. Menarini Diagnostics has entered into an exclusive distribution agreement with Sinocare for the distribution of a new continuous glucose monitoring (CGM) system in Europe.
The agreement covers the registration, promotion, and distribution of Sinocare’s third-generation CGM System.
This system will be introduced to reimbursed markets across more than 20 countries in Europe.
A. Menarini Diagnostics, which is part of the Menarini Pharmaceutical Group, has gained exclusive rights to market this health technology in these regions.
Sinocare’s CGM system is said to offer precise and continuous glucose monitoring.
Sinocare CGM business unit head Jiangfeng Fei said: “The partnership with A. Menarini Diagnostics is a significant milestone in our mission to make our 3rd Generation CGM Systems widely accessible to people with diabetes.
“We are pleased to enter into a strategic partnership with A. Menarini Diagnostics, a leader in the healthcare industry, to bring this innovative diabetes technology to a broader audience.”
A. Menarini Diagnostics will leverage its network, expertise, and resources to ensure that the Sinocare third-generation CGM System reaches those who can benefit most from its advanced features.
This partnership is also expected to increase the availability of Sinocare’s CGM systems across Europe.
A. Menarini Diagnostics general manager and global head Fabio Piazzalunga said: “Securing exclusive rights for the distribution and marketing of this Sinocare 3rd Generation CGM System across various countries aligns with our commitment to providing innovative healthcare solutions.
“We are confident that this long-term partnership will meet the growing demand for advanced diabetes care.”
A. Menarini Diagnostics is a healthcare company specialising in innovative diagnostic solutions. The company empowers healthcare professionals to make accurate, sustainable diagnoses. Its advanced tools enhance health outcomes and improve the quality of life.
Sinocare, founded in 2002, was the first blood glucose meter company listed in China. With a strong presence in Asia, Europe, and North America, Sinocare has expanded its global reach through strategic partnerships and acquisitions, including PTS Diagnostics in the US and Nipro Diagnostic, now known as Trividia Health.
In September 2024, A. Menarini Diagnostics formed a long-term commercial partnership with Nucleix for distribution of the latter’s Bladder EpiCheck test in Europe.
